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Abstract
Background: Ezrin-radixin-moesin-binding phosphoprotein 50 (EBP50) is an adapter protein which has been
shown to play an active role in a wide variety of cellular processes, including interactions with proteins related to
both tumor suppression and oncogenesis. Here we use immunohistochemistry to evaluate EBP50’s expression in
normal donor prostate (NDP), benign prostatic hyperplasia (BPH), high grade prostatic intraepithelial neoplasia
(HGPIN), normal tissue adjacent to prostatic adenocarcinoma (NAC), primary prostatic adenocarcinoma (PCa), and
metastatic prostatic adenocarcinoma (Mets).
Methods: Tissue microarrays were immunohistochemically stained for EBP50, with the staining intensities
quantified using automated image analysis software. The data were statistically analyzed using one-way ANOVA
with subsequent Tukey tests for multiple comparisons. Eleven cases of NDP, 37 cases of NAC, 15 cases of BPH, 35
cases of HGPIN, 103 cases of PCa, and 36 cases of Mets were analyzed in the microarrays.
Results: Specimens of PCa and Mets had the lowest absolute staining for EBP50. Mets staining was significantly
lower than NDP (p = 0.027), BPH (p = 0.012), NAC (p < 0.001), HGPIN (p < 0.001), and PCa (p = 0.006). Additionally,
HGPIN staining was significantly higher than NAC (p < 0.009) and PCa (p < 0.001).
Conclusions: To our knowledge, this represents the first study comparing the immunohistochemical profiles of
EBP50 in PCa and Mets to specimens of HGPIN, BPH, NDP, and NAC and suggests that EBP50 expression is
decreased in Mets. Given that PCa also had significantly higher expression than Mets, future studies are warranted
to assess EBP50’s potential as a prognostic biomarker for prostate cancer.
Background
Prostate cancer is currently the second leading cause of
cancer death in males[1]. Despite this, in the era of
prostate specific antigen (PSA) screening, researchers
have now estimated that clinically insignificant prostate
cancer is actually overdiagnosed at a rate of 29% for
whites and 44% for blacks, the PSA screen resulting in
the detection of cancers that otherwise would only have
been detected during autopsy in up to 15% and 37% of
tumors in whites and blacks, respectively[2].
There is currently a limited amount of information in
t h el i t e r a t u r eo nb i o m a r k e r s with the potential to dis-
cern which cases of prostate cancer have the greatest
potential to metastasize versus remain latent[3]. Evaluat-
ing the expression of tumor suppressor proteins that
have been previously examined in other cancers may
indicate novel biomarkers for prostate cancer that have
the potential to assess individual patient prognosis and
guide therapy selection.
One such biomarker is ezrin-radixin-moesin-binding
phosphoprotein 50 (EBP50), which is also known as Na
+/H+ exchanger regulatory factor 1, or NHERF1. A 50
kDa, 358 amino acid adaptor protein whose gene is
located at 17q25.1, it consists of two PSD-95/Discs
Large/ZO-1 (PDZ) domains and a carboxyl-terminal
region that is capable of binding members of the ezrin-
radixin-moesin (ERM) protein family[4-6]. With its mul-
tiple domains, it has been described as a participant in
at least 30 unique cellular interactions, including those
involving ion transport, secondarily coupled signaling
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oncologically relevant functions for the protein that
have been demonstrated are its ability to recruit the
tumor suppressor PTEN for inactivation of the phospha-
tidylinositol-3-OH kinase (PI3K)/Akt signaling pathway
in glioblastoma multiforme[5,7], as well as an ability to
provide cortical stabilization of b-catenin at cellular
junctions in murine embryonic fibroblast models[8],
both indicative of a tumor suppressor function.
Further supporting this notion, additional work has
shown that an allele for EBP50 was deleted in 28 of 48
examined breast cancer cell lines[9]. Knocking-out exist-
ing EBP50 expression in T47D and MCF7 breast cancer
cell lines has also been shown to lead to increased cell
proliferation[10]. Zheng et al. have additionally noted
that restoring EBP50 expression to a MDA-MB-231
breast cancer line, originally deficient in EBP50, inhib-
ited cell growth and increased apoptosis[11]. Subsequent
to this, the same group prepared a stably transfected
HeLa-EBP50 clone, which also demonstrated decreased
cell growth, suggesting a tumor suppressor role for
EBP50 in cervical cancer as well.
In spite of this, a universal tumor suppressor function
for EBP50 has not been observed. EBP50 has been
shown to be overexpressed in hepatocellular carcinoma
[12]. Cytoplasmic over expression has also been linked
to the progression of colorectal carcinoma[13]. Further-
more, in contrast to the previously described work,
Song et al. have reported that EBP50 immunoreactivity
in breast cancer was positively associated with tumor
stage and lymph node involvement[14], prompting
others to suggest that its role in oncogenesis or tumor
suppression may vary with cellular location, with a
membranous or apical distribution supporting a tumor
suppressor function and a cytoplasmic distribution con-
ferring oncogenic properties [5].
To our knowledge, the expression of EBP50 has never
been studied in prostate cancer. Here, we compare the
immunohistochemical profiles in a series of 11 cases of
normal donor prostate (NDP), 37 cases of normal tissue
adjacent to prostatic adenocarcinoma (NAC), 15 cases
of benign prostatic hyperplasia (BPH), 35 cases of high-
grade prostatic intraepithelial neoplasia (HGPIN), 103
cases of primary prostatic adenocarcinoma (PCa), and
36 cases of metastatic prostatic adenocarcinoma (Mets)
in order to examine if either a tumor suppressor or
oncogenic function for EBP50 can be suggested in pros-
tate cancer, providing further information about its
potential as a diagnostic and/or prognostic biomarker.
Methods
Tissue Microarray Block Preparation
Tissue microarray (TMA) blocks were constructed using
specimens obtained from the Health Sciences Tissue
Bank at the University of Pittsburgh Medical Center,
with the tissue bank rendering the honest broker ser-
vices. All specimens were originally obtained with
informed consent. Cores from the appropriate case spe-
cific paraffin-embedded tissue blocks were assembled
into TMAs as described in a previous protocol[15]. The
final TMAs consisted of 11 cases of NDP, 37 cases of
NAC, 15 cases of BPH, 35 cases of isolated HGPIN (no
accompanying cancer diagnosed), 103 cases of PCa, and
36 cases of Mets. No specimens of HGPIN included in
this study were diagnosed at the time as containing PCa.
All cases were initially prepared so that each one would
be represented at least in triplicate. Due to variations in
TMA processing, however, some cases were only able to
be represented in duplicate. This occurred for three
cases of the HGPIN, three cases of the Mets, three cases
of the NAC, two cases of the BPH, and eight cases of
the PCa. In such instances, these cases were still scored
and included as a part of the final analysis.
Immunohistochemistry
Each TMA block was deparaffinized and then rehy-
drated with incremental ethanol concentrations. Decloa-
ker was then used for heat induced epitope retrieval,
followed by a 5 minute TBS buffer rinse. A Dako auto-
stainer was then used to stain the TMAs with anti-
EBP50 (working dilution 1:400), a mouse monoclonal
antibody (Catalogue # MA1-19291) from Thermo Scien-
tific (Waltham, MA). Immunolabeling was conducted
using Dako Dual Envision + Polymer (Catalogue #
K4061) from Dako (Carpinteria, CA). The slides were
counterstained with hematoxylin and coverslipped.
Scoring of Slides
All slides for this project were scanned as digital whole
slides images (WSI) using ScanScope XT (by Aperio,
Vista, CA). The individual tissue cores for each WSI
were viewed using Aperio ImageScope (Version
11.0.2.716) and scored by applying the Positive Pixel
Count Algorithm to each one. In order to detect the
EBP50 staining, a hue value of 0.1 and hue width of 0.5
was chosen for the algorithm, corresponding to the sug-
gested range for the detection of brown immunostaining
using the software (Aperio Positive Pixel Count Algo-
rithm instruction manual). By analyzing the average
pixel intensity with a predetermined hue value and
width, the stromal tissue and cell nuclei that appear
blue and do not feature the immunostain are negated by
the software and excluded from the final analysis that
determines the average staining intensity. This, in effect,
controls for the glandular to stromal tissue ratio present
in the TMA cores.
The validity of using Aperio software for quantitative
immunohistochemistry has been previously documented
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was then determined by the software for each core, uti-
lizing a formula that sums the intensities of weak, mod-
erate, and strong staining pixels and divides this value
by the total number of weak, moderate, and strong pix-
els. Staining intensities for the software are reported on
a scale of 0-255, corresponding to light transmission
through the specimen. Therefore, higher staining inten-
sities correspond with lower scores on the light trans-
missibility scale. Scores in the range of 220-175 are
classified as weak staining, 175-100 are classified as
moderate staining, and 0-100 are classified as strong
staining. In order to make staining scores more intuitive
in our figures, our results are reported as the difference
between no stain detection (255) and the average stain-
ing intensity as reported by the software, so that higher
values correspond with the higher staining intensities.
This value is referred to as the “staining intensity”
throughout the rest of the manuscript.
The means for each case, and subsequently for each
tissue type were then determined. For the specimens of
adenocarcinoma, the Gleason score and tumor stage,
where available, were also reported. The Clinical TNM,
as opposed to the Pathologic TNM, staging classification
was used to assess the specimens. All means were
reported with standard errors.
One-way ANOVA with subsequent Tukey tests for
multiple comparisons (a = 0.05) were used to compare
the tissue types, PCa carcinoma stages, and PCa Gleason
scores. Graphical analysis was conducted using Micro-
soft Excel 2007 (by Microsoft Corporation, Redmond,
WA) and R: A Language and Environment for Statistical
Computing (R Development Core Team. R Foundation
for Statistical Computing Vienna, Austria. 2011. ISBN 3-
900051-07-0, <http://www.R-project.org>).
Photomicrographs of tissue cores were taken using an
Olympus BX51 microscope using Spot Advanced V4.6
(Diagnostic Instruments, Inc.) software. All images were
taken at 20×.
This study received exempt approval (PRO08040368)
from the University of Pittsburgh Institutional Review
Board.
Results
Patient Ages
The average patient ages with standard deviations for
t h et i s s u et y p e si nt h i ss t u d ya r eN D P3 2±1 3y e a r s ,
NAC 63 ± 6 years, BPH 67 ± 9 years, PIN 63 ± 8 years,
PCa 64 ± 9 years, and Mets 70 ± 10 years.
Staining Intensities
The mean staining scores for NDP, BPH, NAC, HGPIN,
PCa, and Mets were 141.23 ± 2.43, 140.66 ± 2.42,
139.91 ± 2.52, 151.76 ± 2.88, 135.72 ± 1.45, 125.55 ±
2.63 (Figure 1A). Box plots showing the individual stain-
ing scores are featured in Figure 1B. A one-way
ANOVA (p < 0.001), with subsequent Tukey tests for
multiple comparisons, showed significant differences
between Mets and NDP (p = 0.027), NAC (p < 0.001),
BPH (p = 0.012), HGPIN (p < 0.001), and PCa (p =
0.006). Differences were also seen between HGPIN and
PCa (p < 0.001) and NAC (p < 0.009).
Five out of thirty-seven specimens of NAC (13.5%), 1/
15 specimens of BPH (6.7%), 17/35 specimens of
Figure 1 EBP50 staining intensity by prostatic tissue type. A) Mean EBP50 staining score by prostatic tissue type. Significant differences were
seen between Mets and NDP (p = 0.027), NAC (p < 0.001), BPH (p < 0.012), PIN (p < 0.001), and PCa (p = 0.006), with Mets having the lowest
staining of any group. PIN also had the highest staining of any group, and was significantly higher than PCa (p < 0.001) and NAC (p < 0.009)
groups. B) Box plots of EBP50 Staining Intensities by Tissue Type Featuring Individual Cases. It is especially notable that many specimens in the
PCa and Mets classifications feature staining below that of the other tissue classifications. Moreover, only one case of Mets featured a score
above 155, the lowest limit for high intensity staining.
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36 specimens of Mets (2.8%) had staining scores in the
highest intensity category. Although 0/11 specimens of
NDP had staining in the highest intensity category, 4/11
specimens were less than 10 intensity scale points below
the threshold for highest intensity category (36.4%).
When classified by tumor stage, the mean scores were
stage 2, 139.60 ± 2.43 (n = 39), stage 3, 130.66 ± 2.29 (n
= 37), and stage 4, 137.03 ± 2.61 (n = 27). A resultant
one-way ANOVA (p = 0.024) with subsequent Tukey
tests for multiple comparisons showed significant differ-
ences between stage 2 and stage 3 (p = 0.021).
When classified by Gleason score, the average staining
score was 133.13 ± 3.52 (n = 15) for those with a score
of 6 or less, 135.69 ± 2.06 (n = 49) for those with a
score of 7, and 137.13 ± 2.54 (n = 38) for those with a
score of 8 or more. No significant differences were seen
between the Gleason score classifications (p = 0.672).
Staining Patterns
Representative photomicrographs of the TMA cores are
shown in Figure 2. Across most specimens, a cytoplas-
mic EBP50 staining pattern was noted. However, in
many specimens, more prevalent amongst the benign
and pre-cancerous tissues, a membranous or apical
staining pattern was distinctly notable as more predomi-
nant than co-accompanying cytoplasmic staining. Such
cores were noted in 3/11 cases of NDP (27.3%), 11/15
cases of BPH (73.3%), 12/37 cases of NAC (32.4%), 12/
35 cases of HGPIN (34.8%), 10/103 cases of PCa (9.7%),
and 0/36 cases of Mets.
Discussion
In the EBP50 stained specimens, the average staining
intensities were highest in the specimens of HGPIN,
and lowest in the specimens of PCa and Mets. HGPIN
had significantly higher staining than Mets, NAC, and
PCa. Despite the fact that HGPIN was significantly dif-
ferent than the BPH and NDP groups but not the NAC
group, the means were relatively similar between BPH,
NDP, and NAC, suggesting that the staining intensity
does not vary greatly between these classifications.
Previous work has shown that radixin, an ERM pro-
tein and binding partner of EBP50 that is responsible
for linking F-actin to plasma membrane proteins[5,18],
also demonstrated higher absolute staining in specimens
of HGPIN than in other prostatic tissue types, including
PCa and NAC [19]. This finding may indicate that the
higher expression of both proteins in HGPIN may
reflect a unique feature of the pre-cancerous tissue phy-
siology, and that both may be down regulated in speci-
mens of prostatic adenocarcinoma.
Mets tissue had significantly lower staining than all
other tissue types, including PCa, indicating that loss of
EPB50 expression may play a role in select cases of
prostate cancer metastasis. This is further echoed by the
fact that only 1/36 cases of metastatic tissue showed
high intensity range staining for EBP50. Given that
EBP50 has been previously shown in murine fibroblast
models to promote adherens junction stabilization
through mediating the interaction of b-catenin with E-
c a d h e r i n ,i t sl o s so fe x p r e s s ion is plausible with tumor
dissemination[8].
Despite this, however, it is important to note that
these findings may also contain a correlative component
that is not prognostic in nature. While all of the tumors
i nt h i ss t u d yw e r ep r i m a r yt u m o r sa tt h et i m eo fs p e c i -
men retrieval, definitive follow-up information on these
patients was not available. In this sense, from this study
it is not possible to rule out that the decreased EBP50
expression, at least in part, may be due to the metastatic
location itself. The current results, however, indicate
and warrant later phase biomarker studies[20] that will
longitudinally correlate EBP50 expression directly with
patient outcomes to further evaluate its potential to pre-
dict metastatic risk in prostate cancer.
A significant increase in EBP50 staining between Stage
2 and 3 PCa specimens was also observed. It is possible
that this finding represents a change in tumor physiol-
ogy between the two stages, however, given that this
trend was not noted in Stage 4 PCa specimens, it is also
possible that this represents a spurious finding, and
should be further evaluated before definitive conclusions
are reached. No differences were seen between the Glea-
son score classifications.
In general, EBP50’s expression is increased in polar-
ized epithelial cells, such as the liver, kidney, pancreas,
small intestine, and the prostate[5]. Considering the
diverse intracellular roles that have been proposed for
EBP50, it may be difficult to elucidate a clear, singular
mechanism whereby it may promote oncogenesis or
tumor suppression within individual tissue types.
Differing hypotheses to explain to the behavior of
EBP50 in cancer have been proposed, especially given
the multiple studies that seem to support two opposing
functions for EBP50 in cancer [9-11,21]. Zheng, et al
have suggested that in many cases of breast cancer
where EBP50 is expressed, it may not be expressed in
sufficient quantities to halt tumor progression[11].
Others have demonstrated that the hypoxia associated
with tumor necrosis can increase EBP50 (NHERF1),
which increases Na+/H+ activity, in turn decreasing
local pH and promoting tumor dissemination[4,21]. And
while it has been shown that EBP50 can cluster with
EGFR, PDGFR, and the tumor suppressor NF2 to halt
cell signaling and hence cancer progression[11,22-24],
others have posited that EBP50’sP D Zd o m a i n sm a y
actually allow for new tumor-specific interactions[4].
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Page 4 of 8Figure 2 Photomicrographs of TMA cores. Photomicrographs of TMA cores (20×). A) NDP, B) BPH, C) NAC, D) HGPIN, E) PCa, and F) Mets.
Note the predominantly membranous pattern in BPH, which was noted in cores from 11/15 cases. To a lesser degree, this is also noted in the
depicted specimen of HGPIN, although the cytoplasmic staining is also intense, which partially obscures the distinction. In the remainder of
depicted cores, the staining is largely cytoplasmic. No membranous staining was noted in any of the metastatic cores.
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with the hypothesis that EBP50 may have different func-
tions by cellular location, with a tumor suppressor func-
tion associated with a membranous/apical distribution,
and an oncogenic function promoted by a cytoplasmic
location[5]. In support of this hypothesis, previous work
has demonstrated a progression from luminal to cyto-
plasmic EBP50 expression occurs across normal to duc-
tal carcinoma in-situ to invasive and metastatic breast
cancer tissues[25]. While membranous EBP50 has been
shown to stabilize b-catenin at cell membranes[8], non-
stabilized b-catenin is also capable of forming growth-
promoting transcription complexes in the nucleus and
has been prominently associated with hepatocellular car-
cinoma[26]. Hence, it is interesting that an overexpres-
sion of EBP50 with a focal nuclear localization has been
documented in hepatocellular carcinoma[12]. A similar
phenomenon has been noted in colorectal cancer, where
membranous EBP50 loss and increased cytoplasmic
expression has been noted in the colorectal adenoma-
to-carcinoma transition, with subsequent increases in
cellular invasion and epithelial-to-mesenchymal transi-
tion, processes that demonstrated reversibility when
EBP50 was reexpressed at the apical membrane of
intestinal epithelium[13]. Additionally, in normal astro-
cytes, EBP50 has demonstrated a membranous distribu-
tion, while it has demonstrated a cytoplasmic
distribution in many cases ofg l i o b l a s t o m am u l t i f o r m e
[7]. This corresponds with the absence of the EBP50-
binding tumor suppressor PTEN and the activation of
the growth-promoting Akt pathway, which is tradition-
ally silenced by PTEN through recruitment to the
plasma membrane by EBP50[7].
Relating these examples specifically to prostate cancer,
it has been demonstrated that b-catenin can interact
with androgen receptor and increase its transcriptional
activity, hence contributing to prostate cancer progres-
sion[27,28]. Moreover, the tumor suppressor PTEN is
frequently found mutated in prostate cancer, with subse-
quent PI3K/Akt signaling shown to promote cell survi-
val[27,29]. Interestingly, the PI3K/Akt pathway also
increases the stability of b-catenin in prostate cancer
[30]. Based on these findings, it is possible to suggest
that EBP50, under the appropriate circumstances, may
possess a tumor suppressor function in prostate cancer
similar to those described above in other cancer types.
While a cytoplasmic staining pattern for EBP50 was
noted across most specimens examined in this study, a
membranous/apical staining pattern was clearly more
prominent than cytoplasmic staining in many cores,
most commonly in the benign and pre-neoplastic speci-
mens (Figure 2). While cores with clearly more promi-
nent membranous staining were found in 73.3% of BPH
cases studied (Figure 2B), this finding was only noted in
9.7% of cases of PCa and not in any specimens of Mets.
Although an overlap between the expression patterns
still existed between many of the benign and cancerous
specimens, this trend concurs with the above hypothesis
regarding strong membranous expression and tumor
suppression and warrants further study to determine its
potential to assess metastatic risk.
As a final note of interest, in one model of EBP50
function, its PDZ-2 domain has been shown to bind to
the C-terminal ERM-binding domain, inhibiting the
binding of other proteins to the PDZ domains, such as
PTEN and B-catenin[31]. In this same model, when
ezrin, an ERM protein, binds the C-terminal domain,
the PDZ domains are freed up for additional binding
partners. In the intestinal epithelium of ezrin knock-out
mice, EBP50 has been shown to be displaced to the
cytoplasm[5,32]. In light of this, it is an interesting find-
ing that ezrin expression has been inversely correlated
with tumor differentiation in prostate cancer[33], and
that moesin, another ERM protein, showed higher inci-
dences of lymph node metastases when it was associated
with a cytoplasmic distribution as opposed to a mem-
branous one in oral squamous cell carcinoma[34].
Hence, EBP50’s location and function may also be
directly linked to the location and presence of the ERM
proteins that ultimately enable PDZ domain
interactions.
Conclusions
These results provide a basis for the characterization of
the staining patterns and intensities of EBP50 in PCa
a n dM e t si nc o m p a r i s o nt ob e n i g np r o s t a t et i s s u e .T h e
immunostaining was highest in specimens of HGPIN.
Its expression was lowest in Mets, with the expression
in Mets significantly lower than that of all other tissue
groups, including PCa (p = 0.006). As a significant
decrease between Stage 2 and 3 cancer was observed (p
= 0.021), it is also possible that EBP50 expression is
altered with carcinoma stage, although significant differ-
ences were not seen when Stages 2 and 3 were com-
pared to Stage 4. No differences were seen when
comparing the Gleason scores of the PCa specimens.
EBP50 staining was a combination of membranous/
apical and cytoplasmic in the prostatic tissues examined.
Although a clear distinction would not be made in all
cases, a predominant membranous staining pattern was
more commonly observed in benign specimens than in
malignant ones. As an example, 11/15 cases of BPH fea-
tured cores with a readily apparent predominant mem-
branous staining pattern compared to the adjacent
cytoplasm, while this was only observed in 10/103 cases
of PCa and was not seen in any cases of Mets.
It is also important to note, however, as this membra-
nous/cytoplasmic distinction was not noted in all
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that an alternate explanation may account for these
findings. As a general decrease in overall staining inten-
sity was observed between the benign specimens and
the cancerous/metastatic specimens, this lack of mem-
branous staining may simply reflect an overall staining
decrease, making it difficult to appreciate the true ratio
of membranous to cytoplasmic staining from a visual
examination. This is especially true in the cases of meta-
static cancer, where the overall staining is very faint
across all specimens in the first place.
Given that a significant decrease in staining was noted
between specimens of PCa and Mets, further studies of
EBP50 are justified to assess its potential for clinical
usage in prognosis assessment of patients with prostate
cancer.
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